EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Serum 1,5‐Anhydroglucitol Identifies Residual Mortality Risk Beyond Time in Range in Type 2 Diabetes: A Cohort Study

Jiaying Ni, Lei Chen, Hang Su, Jingyi Guo, Chunfang Wang, Yufei Wang, Jingyi Lu, Jian Zhou iD, Tian Xia iD, Feng Jiang iD

Journal of Diabetes · 2026-07 · 18 (8)

DOI: 10.1111/1753-0407.70260 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Diabetes, online erschienen am 04.08.2026. Verfasst von Jiaying Ni und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai…. Hauptthemen laut MEDLINE: Deoxyglucose, Diabetes Mellitus, Type 2, Cardiovascular Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, Shanghai Leading Talent Program of Eastern Talent Plan, Shenzhen Medical Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The combined prognostic value of continuous glucose monitoring (CGM) metrics and circulating glucose biomarkers for predicting mortality in type 2 diabetes has not been fully established, particularly regarding residual risk in patients achieving glycemic targets.

Methods

This cohort study included 3677 patients with type 2 diabetes for a median of 7.4 years follow‐up. Cox proportional hazards models evaluated the associations of baseline CGM‐derived time in range (TIR) (target 70%) and serum 1,5‐anhydroglucitol (1,5‐AG) (threshold 6.0 μg/mL) with all‐cause and cardiovascular mortality in the overall population. We further examined the relationship between 1,5‐AG and mortality within TIR subgroups and compared its performance with metrics of glycemic variability derived from CGM.

Results

During follow‐up, 522 all‐cause deaths and 181 cardiovascular deaths occurred. TIR and 1,5‐AG were moderately correlated and independently predicted mortality, with concurrent low TIR (≤ 70%) and low 1,5‐AG (< 6.0 μg/mL) yielding the highest risk (hazard ratio [HR] 1.82, 95% CI 1.40–2.37). In stratified analyses, reduced 1,5‐AG was significantly associated with increased mortality risk in patients with TIR > 70% (HR 1.69, 95% CI 1.25–2.28), whereas no significant association was observed in those with TIR ≤ 70%. Adding 1,5‐AG improved traditional risk prediction in the former subgroup. Compared with 1,5‐AG, CGM‐derived glycemic variability indices such as mean amplitude of glycemic excursions, coefficient of variation, and standard deviation of glucose showed no significant association with mortality.

Conclusions

TIR and serum 1,5‐AG offer independent and complementary value, with low 1,5‐AG identifying residual mortality risk despite achieving TIR targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeoxyglucoseDiabetes Mellitus, Type 2Cardiovascular DiseasesHumansContinuous Glucose MonitoringBiomarkersFemaleMaleMiddle AgedBlood GlucoseAgedPrognosisRisk FactorsCohort StudiesFollow-Up StudiesProportional Hazards Models

Stichwörter der Autor:innen

1,5‐anhydroglucitolall‐cause mortalitycontinuous glucose monitoringtime in rangetype 2 diabetes

Substanzen

Deoxyglucose1,5-anhydroglucitolBiomarkersBlood Glucose

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai K…
  • Vital Statistical Department, Institute of Health Information, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
  • Department of Gerontology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Clinical Research Center, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

ORCID-Profile: Jian Zhou, Tian Xia, Feng Jiang

Förderung

  • Noncommunicable Chronic Diseases-National Science and Technology Major Project
  • Shanghai Leading Talent Program of Eastern Talent Plan
  • Shenzhen Medical Research Fund
  • Sanming Project of Medicine in Shenzhen
  • Shanghai Action Plan for Science, Technology and Innovation
  • Shanghai Oriental Talent Program (Outstanding Project)
  • Sanming Project of Medicine in Shenzen Municipality

Zitieren

APA

Ni, J., Chen, L., Su, H., Guo, J., Wang, C., Wang, Y., Lu, J., Zhou, J., Xia, T., & Jiang, F. (2026). Serum 1,5‐Anhydroglucitol Identifies Residual Mortality Risk Beyond Time in Range in Type 2 Diabetes: A Cohort Study. Journal of Diabetes, 18(8). https://doi.org/10.1111/1753-0407.70260

Vancouver

Ni J, Chen L, Su H, Guo J, Wang C, Wang Y, et al. Serum 1,5‐Anhydroglucitol Identifies Residual Mortality Risk Beyond Time in Range in Type 2 Diabetes: A Cohort Study. Journal of Diabetes. 2026;18(8). doi:10.1111/1753-0407.70260

BibTeX
@article{Ni2026,
  author = {Ni, Jiaying and Chen, Lei and Su, Hang and Guo, Jingyi and Wang, Chunfang and Wang, Yufei and Lu, Jingyi and Zhou, Jian and Xia, Tian and Jiang, Feng},
  title = {Serum 1,5‐Anhydroglucitol Identifies Residual Mortality Risk Beyond Time in Range in Type 2 Diabetes: A Cohort Study},
  journal = {Journal of Diabetes},
  year = {2026},
  volume = {18},
  number = {8},
  doi = {10.1111/1753-0407.70260}
}
Kostenlos starten →